Preparation and use of n-substituted phenyl-2-pyridone and endoperoxide
By developing N-substituted phenyl-2-pyridone intraperoxide, using photosensitivity reaction to release singlet and triplet oxygen, the problems of low efficacy and major side effects of existing drugs have been solved, and the lung fibrosis and Effective treatment of cancer, especially in lung fibrosis combined with lung cancer, has shown excellent results.
Patent Information
- Application Number
- PCT/CN2024/092532
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-30
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-21
AI Technical Summary
Existing pulmonary fibrosis and cancer treatment drugs such as pirfenidone are low in efficacy and have great side effects, and the treatment of pulmonary fibrosis combined with lung cancer is difficult, and there is a lack of effective means.
A class of N-substituted phenyl-2-pyridone intraperoxide was developed to release singlet and triplet oxygen in the body through photosensitivity reaction, inhibiting the expression of transforming growth factor-β and other factors, and is used to treat pulmonary fibrosis. Lung cancer and other fibrotic diseases.
This inner peroxide has good stability and safety, can synergistically inhibit a variety of therapeutic factors, is significantly better than the marketed drug pirfenidone, has stronger anti-pulmonary fibrosis and anti-cancer effects, and is suitable for a variety of Treatment of fibrosis and cancer.
Smart Images

Figure CN2024092532_21112024_PF_FP_ABST
Abstract
Description
Preparation and application of a class of N-substituted phenyl-2-pyridones and endoperoxides Technical Field
[0001] The present invention belongs to the technical field of organic compound synthesis and medicine, and particularly relates to the preparation and application of a class of N-substituted phenyl-2-pyridones and endoperoxides. Background Art
[0002] Pulmonary fibrosis is a lung disease characterized by fibroblast proliferation and accumulation of extracellular matrix, accompanied by inflammatory damage and structural destruction. It is also considered to be scarring caused by abnormal repair of damaged alveolar tissue. To date, the cause of pulmonary fibrosis remains unknown in most patients, and this condition is also known as idiopathic pulmonary fibrosis. The average survival after diagnosis of idiopathic pulmonary fibrosis is short, with a mortality rate higher than that of most cancers, severely impacting respiratory function and daily life. Lung cancer is one of the most common malignant tumors, with a high global incidence. Non-small cell lung cancer accounts for over 80% of cases, and most patients are diagnosed in the advanced stage, increasing the difficulty of clinical treatment. Lung cancer is also a significant comorbidity in patients with idiopathic pulmonary fibrosis. The incidence of lung cancer in patients with idiopathic pulmonary fibrosis is as high as 48%, significantly higher than in the general population. Currently, there is no specific treatment for idiopathic pulmonary fibrosis; the only approved drugs are pirfenidone and nintedanib. Pirfenidone is a cytokine inhibitor that inhibits transforming growth factor (TGF-β) and fibroblast growth factor (bFGF), thereby suppressing fibroblast activity, reducing cell proliferation, and matrix collagen synthesis. Pirfenidone can delay lung function failure and mitigate disease progression, but it still cannot reverse the progression of pulmonary fibrosis. Chemotherapy is the mainstay of treatment for non-small cell lung cancer, but drug resistance often leads to treatment failure. Pulmonary fibrosis combined with lung cancer is challenging to treat, and currently no effective treatments exist. Because these diseases often occur in the elderly, patients often experience poor lung function and poor tolerance to surgery and chemotherapy. Conventional chemotherapy often leads to lung infections, neutropenia, and respiratory insufficiency. Furthermore, the mortality rate for patients with pulmonary fibrosis combined with lung cancer is several times higher than that for patients with pulmonary fibrosis alone, and no specific treatment is currently available. Fibrosis can also develop during the development and treatment of other cancers, such as liver cancer with liver fibrosis. Therefore, there is an urgent need for drugs that can treat both fibrosis and cancer.
[0003] Pirfenidone, 5-methyl-1-phenyl-2-pyridone, is an oral anti-pulmonary fibrosis drug. It exhibits anti-inflammatory, antioxidant, and anti-fibrotic effects. Since its launch, pirfenidone has been shown to delay lung failure and alleviate disease progression. Furthermore, studies have shown that pirfenidone has certain anti-cancer effects and can slow liver and kidney fibrosis. However, pirfenidone has low efficacy, often requiring higher doses, and is prone to gastrointestinal and skin adverse reactions, as well as exhibiting certain phototoxicity. Modifying and improving the structure of pirfenidone could potentially lead to the development of novel anti-cancer and fibrosis-alleviating drugs, which have important practical applications.
[0004] Singlet oxygen 1 Excited oxygen molecules (O2) act as signaling and stimulatory molecules in many physiological processes. Furthermore, singlet oxygen is a highly reactive species that, at certain doses, can damage tumor cell membranes, proteins, and other biomolecules, causing apoptosis, vascular damage, or inducing immune responses to eliminate tumor cells. Research has shown that singlet oxygen reacts with naphthalene, anthracene, and pyridone via a [4+2] cycloaddition reaction to form endoperoxides. Under certain temperatures, endoperoxides undergo a reverse Diels-Alder reaction to convert to the starting material and release singlet oxygen. While releasing singlet oxygen, endoperoxides also release some molecular oxygen (triplet oxygen). Singlet oxygen, after quenching under physiological conditions, can also be converted to molecular oxygen. Molecular oxygen can alleviate tumor hypoxia, and oxygen therapy is a common treatment option for patients with fibrosis. Singlet oxygen delivery systems designed based on endoperoxides may provide novel treatment options for various diseases, including fibrosis, cancer, bacterial infections, Alzheimer's disease, coagulation disorders, and ischemic injury.
[0005] Summary of the Invention
[0006] One object of the present invention is to provide a compound of formula I or a pharmaceutically acceptable salt thereof:
[0007] Among them, R 1 、R 3 Each is independently selected from hydrogen, deuterated methyl, C1-C10 alkyl, carboxyl, C1-C5 fluoroalkyl, nitro, and C1-C10 ester.
[0008] R 4 -R 8 Each is independently selected from hydrogen, C1-C5 deuterated alkyl, C1-C5 fluoroalkyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C10 alkylamino, nitro, cyano, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 thioether.
[0009] R is independently a C1-C5 alkyl group.
[0010] Another object of the present invention is to provide a pharmaceutical composition comprising one or more of the above-mentioned compounds or pharmaceutically acceptable salts thereof.
[0011] The pharmaceutical composition further comprises a carrier and / or pharmaceutical excipients.
[0012] The preparation method of the compound comprises the following steps:
[0013] (1) Compound 1 and Compound 2 react in the presence of potassium carbonate and cuprous iodide to obtain Compound P;
[0014] (2) Compound P reacts in the presence of a photosensitizer, an oxygen environment, and light irradiation to obtain compound E.
[0015] Among them, R 1 、R 3 、R 4 -R 8 The definition of is the same as that in formula I.
[0016] In some specific preparation methods, the reaction solvent in step (1) is one or more high-boiling-point solvents such as N,N-dimethylformamide and dimethyl sulfoxide. The reflux reaction temperature is between 150-200°C. The amount of iodobenzene 2 and potassium carbonate used is 1-3 times the amount of 2-pyridone (by mole). The amount of cuprous iodide used is 2%-20% (by mole) of 2-pyridone.
[0017] In some specific preparation methods, the reaction solvent in step (2) can be one or more solvents such as chloroform, dichloromethane, ether, methanol, ethanol, toluene, benzene, DMF, ethyl acetate, water, deuterated reagents, etc. The reaction temperature is -20°C to room temperature, preferably an ice-water bath, 0°C, an ice bath, a room temperature water bath or below 0°C. The reaction can be carried out at room temperature, but the high temperature evaporation of the solvent due to red light irradiation should be avoided. The irradiation light source can also use a light source of other wavelengths (425-750nm). The gas environment can be oxygen, a gas containing oxygen, or a direct open reaction. Methylene blue / red light can be replaced with other common photosensitizers and light sources of corresponding wavelengths, such as BODIPY / red light.
[0018] The deuterated reagent is selected from one or more of deuterated chloroform, deuterated methanol, deuterated benzene, and deuterated water;
[0019] The photosensitizer is selected from methylene blue, fluoroborane, hematoporphyrin, dihydrochlorin e6, pyropheophorbide-a, pyropheophorbide-a hexyl ether, phenothiazine derivatives, phenoxazine derivatives, porphyrin photosensitizers or phthalocyanine photosensitizers.
[0020] The present invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof in preparing a medicament:
[0021] Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug that is converted into N-substituted phenyl-2-pyridone in vivo and releases singlet oxygen and triplet oxygen:
[0022] Among them, R 1 、R 3 、R 4 -R 8 The definition of is the same as that in formula I.
[0023] Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of the following medicaments:
[0024] Drugs that inhibit the expression of transforming growth factor-β (TGF-β), monocyte chemoattractant protein-1 (MCP-1), and serum inflammatory factor interleukin-1β (IL-1β), while also upregulating heme oxygenase-1 (HO-1); or
[0025] Drugs for treating or improving diseases or inflammation involving one or more factors including TGF-β, MCP-1, IL-1β, HO-1, TNF-α, IL-6, IFN-γ, bFGF, PDGF, NLRP3, CAT, and SOD.
[0026] Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for improving or treating fibrosis.
[0027] The fibrosis is pulmonary fibrosis, liver fibrosis, renal fibrosis, and myocardial fibrosis. Pulmonary fibrosis particularly refers to idiopathic pulmonary fibrosis, and renal fibrosis particularly refers to renal interstitial fibrosis. In addition, it also has therapeutic effects on kidney damage diseases including acute kidney injury, chronic kidney disease, and end-stage renal disease.
[0028] Use of the compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating cancer or inflammation.
[0029] The cancers include lung cancer, non-small cell lung cancer, breast cancer, liver cancer, prostate cancer, and pancreatic cancer.
[0030] The medicine can alleviate non-alcoholic fatty liver inflammation, non-alcoholic fatty liver disease, and liver inflammation, vacuolization, necrosis and other diseases.
[0031] Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis combined with lung cancer, especially idiopathic pulmonary fibrosis combined with lung cancer.
[0032] The drug in the application can be prepared into tablets, capsules, granules, powders, oral preparations, injections, microcapsules, suppositories, pills, aerosols, sprays, powder inhalers, syrups, alcoholic preparations, tinctures, lotions, and films, and one or more of the above dosage forms can be selected for treatment. In addition, the drug can also be prepared into liposomes or micelles for administration.
[0033] The medicine is administered orally, intravenously, by inhalation through the respiratory tract, topically, or sublingually.
[0034] The drugs used in the application include:
[0035] At least one compound of formula I; and / or
[0036] carrier; and / or
[0037] pharmaceutical excipients;
[0038] The carrier is selected from one or more of metal nanocarriers, non-metal nanocarriers, liposomes, lactose, sucrose, gelatin, hard magnesium sulfate, and stearic acid;
[0039] The pharmaceutical excipients are selected from one or more of diluents, binders, disintegrants, lubricants, glidants, flavoring agents, coating agents, gelatin capsule shells, latent solvents, propellants, surfactants, preservatives, and freeze-drying protective agents.
[0040] The drug used in the application is prepared into a liposome or micelle form drug.
[0041] Another object of the present invention is to provide a class of N-substituted phenyl-2-pyridone compounds for use in treating cancer and alleviating fibrosis.
[0042] Use of the compound of formula II in the preparation of drugs for treating liver fibrosis, kidney fibrosis and myocardial fibrosis.
[0043] The compound of formula II is used in the preparation of drugs for treating lung cancer, breast cancer, liver cancer, prostate cancer and pancreatic cancer.
[0044] Among them, R 9 、R 10 、R 11 、R 12 、R 13 Each is independently a hydrogen atom, a deuterated methyl group, a halogen group, a hydroxyl group, a cyano group, an amino group, a nitro group, a trifluoromethyl group, a carboxyl group, an amide group having 1 to 6 carbon atoms, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a thioether group having 1 to 6 carbon atoms, or the like.
[0045] Some specific compounds, R9 、R 10 、R 11 、R 12 、R 13 Each is independently a hydrogen atom, a methyl group, an ethyl group, a deuterated methyl group, a trifluoromethyl group, a butyl group, a halogen group, a hydroxyl group, a cyano group, an amino group, a carboxyl group, a methoxy group, an ethoxy group, or a methylthio group.
[0046] Some specific compounds, R 9 、R 10 、R 11 、R 12 、R 13 Each is independently a hydrogen atom, a methyl group, an ethyl group, a deuterated methyl group or a trifluoromethyl group.
[0047] Specifically, the compound is selected from the following structures:
[0048] A drug for treating liver fibrosis, renal fibrosis, myocardial fibrosis, lung cancer, breast cancer, liver cancer, prostate cancer or pancreatic cancer, comprising at least one compound of formula II or a pharmaceutically acceptable salt thereof.
[0049] The drug dosage forms include tablets, capsules, granules, powders, oral preparations, injections, microcapsules, and suppositories, and can also be prepared into liposomes or micelles for administration. The drug can be used alone or in combination with other drugs.
[0050] The medicine is administered orally, intravenously, by inhalation through the respiratory tract, topically, or sublingually.
[0051] The cancers treated by the drug include one or more of lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer and the like.
[0052] The drug can alleviate one or more diseases such as pulmonary fibrosis, liver fibrosis, renal fibrosis, myocardial fibrosis, or diseases induced by fibrosis. In addition, it also has a therapeutic effect on kidney damage diseases including acute kidney injury, chronic kidney disease, and end-stage renal disease.
[0053] The medicine can alleviate non-alcoholic fatty liver inflammation, non-alcoholic fatty liver disease, and liver inflammation, vacuolization, necrosis and other diseases.
[0054] This invention investigates the efficacy of N-substituted phenyl-2-pyridone compounds with various substituents on the phenyl ring, specifically compounds with no substituents on the pyridone structure but with substituents on the phenyl ring, in treating cancer and alleviating fibrotic diseases. The anti-pulmonary fibrosis effects of these compounds have been reported in a previous patent filed by the inventors. This patent discloses the results of these compounds in treating cancer, particularly lung cancer, breast cancer, liver cancer, prostate cancer, and pancreatic cancer, as well as in alleviating fibrotic diseases such as liver fibrosis, renal fibrosis, and myocardial fibrosis.
[0055] The present invention provides a class of N-substituted phenyl-2-pyridone compounds for use in treating cancer and alleviating fibrosis, including a class of N-substituted phenyl-2-pyridone compounds and their medically acceptable salts. Conventional excipients in the pharmaceutical field can also be added to prepare conventional dosage forms such as tablets, capsules, granules, powders, oral liquids, and injections. Pharmaceutically acceptable excipients, auxiliary ingredients, or other carriers such as solvents, diluents, binders, disintegrants, lubricants, glidants, flavoring agents, coating agents, gelatin capsule shells, latent solvents, propellants, surfactants, preservatives, and lyoprotectants can also be included. In addition, the compounds can be prepared into liposomes or micelles for administration.
[0056] Advantages and beneficial effects of the present invention:
[0057] The N-substituted phenyl-2-pyridone endoperoxide provided by the present invention can be prepared in batches by a simple chemical synthesis method, and has good stability and can be stored for a long time. This type of endoperoxide integrates endoperoxide, N-substituted phenyl-2-pyridone, singlet oxygen and triplet oxygen multiple therapeutic factors, that is, the therapeutic effect of a single factor can be brought into play, while achieving the purpose of the synergistic treatment of several factors. The endoperoxide can inhibit the expression of factors such as transforming growth factor-β (TGF-β), monocyte chemoattractant protein-1 (MCP-1), serum inflammatory factor interleukin-1β (IL-1β) and upregulate heme oxygenase-1 (HO-1), and the anti-pulmonary fibrosis effect is better than that of the listed drug pirfenidone. The endoperoxide of the present invention independently or collaboratively realizes the treatment of pulmonary fibrosis, liver fibrosis, renal fibrosis, myocardial fiber, lung cancer, lung cancer combined with lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer by multiple therapeutic factors, is suitable for multiple dosage forms and carriers, and is expected to become a first-line drug for the treatment of multiple fibrosis and cancer.
[0058] The novel therapeutic applications of a class of N-substituted phenyl-2-pyridone compounds provided by this invention demonstrate that compounds lacking substituents on the pyridone ring but containing methyl substituents on the phenyl ring can effectively treat cancer, particularly lung cancer, breast cancer, liver cancer, prostate cancer, and pancreatic cancer, and alleviate fibrosis, particularly liver fibrosis, kidney fibrosis, and myocardial fibrosis. Furthermore, safety assessments have demonstrated that the developed drug has a good safety profile, exhibiting therapeutic efficacy without significant damage to other organs. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] FIG1 is the general structural formula of the compound of the present invention.
[0060] FIG2 is a graph showing the yield of P5, singlet oxygen, and triplet oxygen released by a representative compound E5.
[0061] FIG3 is a graph showing singlet oxygen release from a representative compound E5;
[0062] Among them, (3a) is the singlet oxygen release graph using SOSG as a probe; (3b) is the singlet oxygen release graph using DPBF as a probe.
[0063] FIG4 is a graph showing the serum hydroxyproline content, lung coefficient (lung weight / body weight) and TGF-β1 mRNA expression in mice undergoing an anti-pulmonary fibrosis experiment;
[0064] Among them, (4a) is a graph showing the hydroxyproline content; (4b) is a graph showing the lung coefficient (lung weight / body weight); and (4c) is a graph showing the TGF-β1 mRNA expression.
[0065] FIG5 is an image of α-SMA immunofluorescence, HE staining, and MASSON staining of lung tissue sections of mice in the anti-pulmonary fibrosis experiment.
[0066] Figure 6 shows the levels of AST, ALT, AKP, BUN, and SCR in the serum of mice undergoing an anti-pulmonary fibrosis experiment.
[0067] FIG7 is a graph showing the effects of endoperoxide E5 on A549 lung cancer cells in MTT test, HIF-1α expression test, singlet oxygen release test, and apoptosis test;
[0068] Among them, (7a) is the MTT test graph of E5 on A549 cancer cells; (7b) is the HIF-1α expression graph of E5 on A549 cancer cells; (7c) is the singlet oxygen release test graph of E5 on A549 cancer cells; (7d) is the apoptosis double staining experiment graph of E5 on A549 cancer cells.
[0069] FIG8 is a graph showing the tumor volume, tumor weight, and HE and immunofluorescence sections of tumor tissue in mice during the anti-cancer experimental treatment process;
[0070] Among them, (8a) is a graph showing the changes in mouse tumor volume; (8b) is a graph showing the changes in mouse tumor weight; (8c) is a HE staining graph of mouse tumor tissue; (8d) is an immunofluorescence section graph of mouse tumor
[0071] FIG9 is a diagram of serum biochemical analysis and HE staining of mouse organs in an anti-cancer experiment;
[0072] Among them, (9a) is a biochemical analysis diagram of mouse serum; (9b) is a HE staining diagram of mouse lung tissue, liver tissue, spleen tissue, kidney tissue and heart tissue sections.
[0073] Figure 10 shows the curve of mouse tumor volume changes in the anticancer experiment of compound P10, the pictures of mouse tumors after treatment, and the tumor volume size.
[0074] FIG11 shows HE staining images of other organs of mice after treatment (11a), the ALT, AST, BUN and SCr levels in mouse serum (11b), and the weight change curve of mice during treatment (11c). DETAILED DESCRIPTION
[0075] Pharmaceutically acceptable salts of compounds of formula (I) are formed by adding pharmaceutically acceptable acids. Examples of salts include, but are not limited to, nitrates, hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, hydrogen phosphates, acetates, benzoates, succinates, fumarates, maleates, lactates, citrates, tartrates, gluconates, pyrosulfinates, benzenesulfonates, and p-toluenesulfonates.
[0076] The term "halogen" represents a fluorine, chlorine, bromine or iodine atom.
[0077] The term "C1-C10 alkyl" refers to a straight-chain or branched, saturated, aliphatic hydrogen-carbon group having 1 to 10 carbon atoms. Examples of C1-C10 alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, n-pentyl, n-hexyl, n-octyl, and n-octyl.
[0078] The term "C1-C5 fluoroalkyl" refers to a linear or branched, saturated, aliphatic hydrogen carbon group having 1 to 5 carbon atoms and containing one or more fluorine atom substituents. Examples of C1-C5 fluoroalkyl are trifluoromethyl, 1,1,1,2-tetrafluoroethyl, perfluoroethyl, perfluoropropyl, and perfluorohexyl.
[0079] The term "C1-C10 ester group" refers to an ester group having 1 to 10 carbon atoms obtained by dehydration of a linear or branched, saturated, fatty alcohol or a linear or branched, fatty acid. Examples of C1-C10 ester groups are wait.
[0080] The term "C1-C10 alkoxy" refers to a straight or branched, saturated, aliphatic alkoxy group having 1 to 10 carbon atoms. Examples of C1-C10 alkoxy are methoxy, ethoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, and the like.
[0081] The term "C1-C10 thioether group" refers to a linear or branched, saturated, aliphatic thioether group having 1 to 10 carbon atoms. Examples of C1-C10 thioether groups are methylthio, ethylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, and the like.
[0082] The term "C1-C5 deuterated alkyl" refers to a straight-chain or branched, saturated, aliphatic hydrocarbon group having 1 to 5 carbon atoms and containing at least one deuterium atom. Examples of C1-C5 deuterated alkyl groups are deuterated methyl, deuterated ethyl, deuterated propyl, deuterated n-butyl, deuterated isobutyl, deuterated n-pentyl, and the like.
[0083] -COOR and -CONR refer to
[0084] The term "C1-C10 alkylamino" refers to a straight-chain or branched, saturated, aliphatic alkylamino group having 1 to 10 carbon atoms. Examples of C1-C10 alkylamino groups are methylamino, ethylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, tert-butylamino, and the like.
[0085] The following examples are provided to help understand the present invention, but they are not intended to limit the present invention.
[0086] A class of drugs capable of treating pulmonary fibrosis, lung cancer, and pulmonary fibrosis combined with lung cancer is disclosed, along with a method for synthesizing such compounds. The present invention creatively develops N-substituted phenyl-2-pyridone endoperoxides, which release N-substituted phenyl-2-pyridone (pirfenidone analogs or pirfenidone), singlet oxygen, and triplet oxygen in vivo to treat pulmonary fibrosis, lung cancer, and pulmonary fibrosis combined with lung cancer.
[0087] Specifically, N-substituted phenyl-2-pyridone endoperoxide or a pharmaceutically acceptable salt thereof has the following structure:
[0088] Among them, R 1 、R 3 Each is independently selected from hydrogen, deuterated methyl, C1-C10 alkyl, carboxyl, trifluoromethyl, nitro, and C1-C10 ester.
[0089] R 4 -R 8Each is independently selected from hydrogen, C1-C5 deuterated alkyl, C1-C5 fluoroalkyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C10 alkylamino, nitro, cyano, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 thioether.
[0090] R is independently a C1-C5 alkyl group.
[0091] Some specific N-substituted phenyl-2-pyridone endoperoxides, R 1 、R 3 Each is independently selected from hydrogen, deuterated methyl, C1-C5 alkyl, and trifluoromethyl.
[0092] R 4 -R 8 Each is independently selected from hydrogen, C1-C5 deuterated alkyl, C1-C5 fluoroalkyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C10 alkylamino, nitro, cyano, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 thioether.
[0093] R is independently a C1-C5 alkyl group.
[0094] Some specific N-substituted phenyl-2-pyridone endoperoxides, R 1 、R 3 Each is independently selected from hydrogen, deuterated methyl, trifluoromethyl, and methyl.
[0095] R 4 -R 8 Each is independently selected from hydrogen, C1-C5 deuterated alkyl, C1-C5 fluoroalkyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C10 alkylamino, nitro, cyano, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 thioether.
[0096] R is independently a C1-C5 alkyl group.
[0097] Some specific N-substituted phenyl-2-pyridone endoperoxides, R 1 、R 3 Each independently selected from hydrogen, methyl;
[0098] R 4 -R 8Each is independently selected from hydrogen, C1-C5 deuterated alkyl, C1-C5 fluoroalkyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C10 alkylamino, nitro, cyano, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 thioether.
[0099] R is independently a C1-C5 alkyl group.
[0100] Some specific N-substituted phenyl-2-pyridone endoperoxides, R 1 、R 3 Each is independently selected from hydrogen, deuterated methyl, trifluoromethyl, and methyl.
[0101] R 4 -R 8 Each is independently selected from hydrogen, deuterated methyl, trifluoromethyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C5 alkylamino, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, and C1-C5 sulfide.
[0102] R is independently a C1-C5 alkyl group.
[0103] Some specific N-substituted phenyl-2-pyridone endoperoxides, R 1 、R 3 Each is independently selected from hydrogen, deuterated methyl, and methyl.
[0104] R 4 -R 8 Each is independently selected from hydrogen, deuterated methyl, methyl, ethyl, tert-butyl, trifluoromethyl, F, Cl, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, -COOCH3, -COOtBu, -CONHCH3, methoxy, ethoxy, nitro, and cyano.
[0105] Some specific N-substituted phenyl-2-pyridone endoperoxides are selected from the following structures:
[0106] The preparation method of N-substituted phenyl-2-pyridone endoperoxide, the synthetic route is as follows:
[0107] (1) 2-pyridone 1, iodobenzene 2, potassium carbonate, cuprous iodide and DMF were placed in a reaction flask and refluxed under argon protection. After the reaction was completed, the mixture was cooled to room temperature, filtered, and the filtrate was decolorized by adding activated carbon. The decolorized solution was evaporated to dryness under reduced pressure, 10% acetic acid was added, and the mixture was stirred at 70°C. After standing for stratification, the upper aqueous phase was taken and sodium hydroxide solution was added to adjust the pH to 13, and the mixture was placed in a refrigerator overnight for crystallization. The crude product was heated to reflux with ethyl acetate, filtered while hot, and the filtrate was cooled for crystallization. Filtered, the filter cake was dried under reduced pressure to obtain pure product P.
[0108] (2) Compound P, a catalytic amount of methylene blue, and chloroform were placed in a reaction flask, irradiated with red light (620-625 nm) under oxygen protection, stirred in an ice-water bath, and the reaction was monitored by TLC. After the reaction, the methylene blue was removed by filtration using silica gel (or activated carbon). The filtrate was evaporated to dryness under reduced pressure to obtain pure compound E.
[0109] Application of N-substituted phenyl-2-pyridone endoperoxides
[0110] The endoperoxide developed by the present invention can release N-substituted phenyl-2-pyridone, singlet oxygen, and triplet oxygen at a certain temperature (such as 37°C in the human body). The N-substituted phenyl-2-pyridone endoperoxide is mainly used to treat pulmonary fibrosis, lung cancer, and pulmonary fibrosis combined with lung cancer.
[0111] Pulmonary fibrosis in mice was induced using bleomycin and treated with the endoperoxides developed in this invention. Following treatment, lung tissue was stained with HE, Masson's, and immunofluorescence staining, and serum hydroxyproline levels were measured. The results demonstrated that the compounds exhibited excellent anti-fibrotic effects, with some, such as E5, demonstrating superior anti-fibrotic effects compared to the marketed drug pirfenidone.
[0112] The marketed drug pirfenidone reduces cell proliferation and matrix collagen synthesis by inhibiting factors such as TGF-β, while exerting anti-inflammatory and antioxidant effects by inhibiting the secretion of IL-1β and other inflammatory mediators and reducing lipid peroxidation. Compared with pirfenidone, the endoperoxides involved in the present invention can significantly inhibit the expression of factors that promote pulmonary fibrosis, such as TGF-β and MCP-1. It is worth noting that, as a singlet oxygen carrier, the endoperoxides involved in the present invention not only do not upregulate inflammatory factors, but are more excellent in anti-inflammatory effect than pirfenidone, further verifying the clinical application potential of the series of compounds in anti-pulmonary fibrosis. In addition, heme oxygenase-1 (HO-1) in the pulmonary fibrosis model group was significantly downregulated compared with the blank group, while representative endoperoxides can significantly upregulate heme oxygenase-1, close to normal physiological levels, and the upregulation effect is far superior to pirfenidone.
[0113] The anti-lung cancer properties of endoperoxides were evaluated at both the cellular and animal levels. The experimental results demonstrated that the endoperoxides described in this invention can efficiently release singlet and triplet oxygen within cancer cells. Singlet oxygen capture probes were used to successfully verify the release of singlet oxygen within cells. Apoptosis experiments demonstrated singlet oxygen-induced apoptosis. MTT experiments confirmed the potent anti-cancer properties of the compounds. Cell migration experiments demonstrated that endoperoxides can successfully inhibit the migration of lung cancer cells. Animal anti-lung cancer experimental results demonstrated that N-substituted phenyl-2-pyridone endoperoxides can effectively inhibit tumor growth in living animals.
[0114] Safety assessment results showed that after endoperoxide treatment, multiple serum indicators (AST, ALT, AKP, BUN, and SCR) in mice remained normal. Other organs, such as the heart, liver, spleen, and kidneys, showed no significant damage. The lung coefficient and overall body weight changes were also normal. These results demonstrate that the drug developed by the present invention has excellent safety and bioavailability, and has potential for clinical application.
[0115] Example 1: Preparation of representative compounds P5, E5
[0116] Compound 1a (20 g), iodobenzene 2a (68.8 g, 1.5 equiv.), potassium carbonate (32.0 g, 1.1 equiv.), cuprous iodide (4 g, 10 mol%), and DMF (300 mL) were placed in a 500 mL reaction flask and refluxed at 150°C for 10 hours under argon protection. After the reaction, the mixture was cooled to room temperature and filtered. The filter cake was washed three times with DMF. The filtrates were combined and decolorized with activated carbon. The decolorized solution was evaporated to dryness under reduced pressure, 100 mL of 10% acetic acid was added, and the mixture was stirred at 70°C for 30 minutes. After standing for separation, the upper aqueous phase was collected, and the lower oily substance was extracted twice with 10% acetic acid. The aqueous phases were combined. Sodium hydroxide solution was added to the aqueous phase to adjust the pH to 13 and the mixture was placed in a refrigerator overnight for crystallization. 100 mL of ethyl acetate was added to the crude product obtained by vacuum drying, and the mixture was heated to reflux. The mixture was filtered while hot and the filtrate was cooled for crystallization. The filter cake was filtered and dried under reduced pressure to obtain pure product P5: 1 H NMR (400MHz, CDCl3) δ7.49–7.46(m,2H),7.42–7.37(m,3H),7.26(d,J=6.9Hz,1H),7.23(d,J=6.9Hz,1H),6.16(t,J=6.8Hz,1H),2.19(s,3H); 13 C NMR (100MHz, CDCl3) δ162.8,141.4,136.9,135.4,130.8,129.2,128.2,126.6,105.6,17.4.
[0117] Compound P5 (15 g), methylene blue (5 mg), and chloroform (100 mL) were placed in a reaction flask. Under oxygen protection, the mixture was irradiated with red light (620-625 nm). The reaction was stirred in an ice-water bath and monitored by TLC. After completion of the reaction, the methylene blue was removed by filtration using silica gel (or activated carbon), and the filtrate was evaporated to dryness under reduced pressure to obtain compound E5. Yield: 100%. 1 H NMR (400MHz, CDCl3) δ7.43–7.39(m,2H),7.32–7.27(m,3H),6.97–6.93(m,1H),6.59–6.57(m,1H),6.08–6.06(m,1H),1.69(s,3H); 13 C NMR (100MHz, CDCl3) δ168.3,138.2,134.0,129.4,126.9,123.7,86.1,82.1,14.7.
[0118] Example 2: Half-life and yield analysis of P5, singlet oxygen, and triplet oxygen release from compound E5 and singlet oxygen capture experiments
[0119] Half-life of release of P5, singlet oxygen and triplet oxygen: Endoperoxide E5 releases P5, singlet oxygen and triplet oxygen through reverse cycloaddition reaction. The whole process follows the first-order kinetic rate equation, which is expressed by t 1 / 2 =0.693 / k formula can be used to calculate the half-life. The specific experimental procedure is as follows: weigh about 2 mg of endoperoxide E5, dissolve it in deuterated water and place it in a 37°C water bath. The nuclear magnetic resonance hydrogen spectrum of the solution is tested at 6 hours, 10 hours, 23 hours and 35 hours respectively. The half-life of the reverse cycloaddition reaction is calculated based on the characteristic peaks of E5 and P5 between 6.25-6.75 ppm: t 1 / 2 = 11.9 hours (37°C, in deuterated water).
[0120] Yields of P5, singlet oxygen, and triplet oxygen released: Tetramethylethylene was used as a singlet oxygen trapping agent, and the yields of P5, singlet oxygen, and triplet oxygen released from the reverse cycloaddition reaction of E5 were calculated using proton nuclear magnetic resonance spectroscopy according to the above method. The results showed that after the complete reverse reaction of 1 mol of E5, 1 mol of P5, 0.5 mol of singlet oxygen, and 0.5 mol of triplet oxygen were released (as shown in Figure 2).
[0121] Furthermore, these results demonstrate that compounds such as the endoperoxide E5 exhibit moderate water solubility and are fully converted to P5 in aqueous solution, releasing both singlet and triplet oxygen. The reverse cycloaddition of the endoperoxides produces no other impurities, demonstrating the high potential for drug development and clinical application of these compounds.
[0122] Singlet oxygen capture assay: SOSG and DPBF were used as singlet oxygen capture agents, respectively, to monitor the release of singlet oxygen from the compounds. The experimental procedure was as follows: Representative compound E5 (375 μM) and SOSG (singlet oxygen capture agent, 12.5 μM) were dissolved in PBS. Fluorescence emission was monitored using a fluorimeter at different time periods at 37°C in the dark. An increase in the 530 nm peak intensity indicated that endoperoxides were able to efficiently release singlet oxygen (as shown in Figure 3a). Representative compound E5 (750 μM) and DPBF (singlet oxygen capture agent, 37.5 μM) were dissolved in DMF. Absorption at 417 nm was monitored using a UV-visible spectrophotometer at different time periods at 37°C in the dark to analyze singlet oxygen release. A change in the 417 nm peak indicated that endoperoxides were able to efficiently release singlet oxygen (as shown in Figure 3b).
[0123] Example 3: Preparation of Compounds E1-E4, E6-E18, E37-E72, E73a-E124a
[0124] The synthesis methods of compounds E1–E4, E6–18, E37-E72, and E73a-E124a refer to the synthesis of compound E5, where the structures of 2-pyridone and iodobenzene used are as follows:
[0125] Compounds E1–E4, E6–E18, E37-E72, and E73a-E124a were all structurally identified.
[0126] Example 4: Anti-pulmonary fibrosis experiment
[0127] 4.1 Experimental process of endoperoxide anti-pulmonary fibrosis
[0128] Mice were randomly divided into a blank control group, a model group, a pirfenidone-treated group, an N-substituted phenyl-2-pyridone-treated group, and an N-substituted phenyl-2-pyridone endoperoxide-treated group. After acclimation for 3 days (weighing approximately 20 g), the mice were surgically induced with a bleomycin solution (2 mg / ml) on the 4th day. Three days after modeling, oral administration began. The drug was prepared in a 0.5% sodium carboxymethylcellulose (CMC-Na) solution and administered to each mouse at a dose of 400 mg / kg. The blank control group and the model group received the same dose of CMC-Na solution. During the oral administration, the mice were measured for body weight and survival. Sixteen days after administration, the mice were sacrificed by eye removal, blood collection, and cervical dislocation. Lungs and other organs were collected. A portion of the lung tissue and other tissues were fixed in 4% neutral formalin, and a portion was treated with liquid nitrogen and stored at -80°C for histological observation and subsequent testing of relevant indicators.
[0129] 4.2 Analysis of the experimental results of endoperoxides against pulmonary fibrosis
[0130] 4.2.1 Analysis of Hydroxyproline Content in Mouse Serum
[0131] Hydroxyproline (HYP), a non-essential amino acid unique to collagen and a major component of collagen tissue, can be used to assess the degree of fibroblast activation. The results of serum HYP levels in mice from each group are shown in Figure 4a. Compared with the serum HYP levels in the blank group (206±4 ng / ml), the HYP levels in the model group (360±7 ng / ml) were significantly increased, demonstrating more severe fibrosis in the mice. The HYP levels in the pirfenidone-treated mice were 286±4 ng / ml, demonstrating a significant effect in alleviating pulmonary fibrosis. The HYP levels in the P5-treated mice were 317±5 ng / ml, demonstrating that P5 has a certain anti-pulmonary fibrosis effect. The HYP levels in the E5-treated mice were 218±4 ng / ml, close to those in the blank group (206±4 ng / ml), indicating that E5's anti-pulmonary fibrosis effect is superior to that of the marketed drug pirfenidone. Hydroxyproline levels after treatment were close to normal values.
[0132] The anti-pulmonary fibrosis efficacy of compounds E1–E18, E37-E41, E44-E49, E51, E55-E59, E62-E63, E66, E70, and E73a-E124a was higher than that of pirfenidone. The test data of some compounds are given in the form of the following table, where the test process and method refer to Examples 4.1 and 4.2.
[0133] Table 1 Anti-pulmonary fibrosis experimental results of a series of compounds Note: A represents the serum HYP content of mice after treatment is 200-250 ng / ml; B represents the serum HYP content of mice after treatment is 250-300 ng / ml; C represents the serum HYP content of mice after treatment is 300-360 ng / ml; D represents the serum HYP content of mice after treatment is greater than 360 ng / ml.
[0134] 4.2.2 Lung coefficient
[0135] The lung coefficient (lung weight / body weight) is a key measurement in animal experiments. As shown in Figure 4b, the lung coefficient of the model group increased slightly compared to the blank group. However, compared to the blank group, none of the three treatment groups (pirfenidone, P5, and E5) showed significant changes in the lung coefficient, further demonstrating the excellent safety and therapeutic efficacy of E5.
[0136] 4.2.3 Analysis of lung coefficient mRNA expression
[0137] After the treatment, mRNA levels were analyzed by fluorescence quantitative PCR. The results showed that the endoperoxide treatment group was able to significantly downregulate factors such as TGF-β, MCP-1, and IL-1β, with an inhibitory effect superior to that of the marketed drug pirfenidone (Figure 4c). In addition, endoperoxides were able to significantly upregulate HO-1, close to normal physiological levels, and by regulating oxidative stress and protecting the body, the effect was far superior to that of pirfenidone. The above results indicate that the endoperoxides of the present invention can effectively resist pulmonary fibrosis and inhibit inflammatory-related factors.
[0138] 4.2.4 Analysis of lung tissue pathological changes
[0139] Lung tissue sections were stained with HE, MASSON, and α-SMA immunofluorescence to compare lung histopathological changes in the blank group, model group, pirfenidone-treated group, P5-treated group, and E5-treated group. As shown in Figure 5, the lung tissue structure in the blank group was clear, with no thickening of the alveolar septa, no edema, no obvious myofibroblasts, no signs of inflammation or pulmonary fibrosis, and no significant exudates within the alveolar cavities. The model group showed severe alveolar structural damage, severe atrophy and collapse, a significant increase in collagenous lung fibers, and a large infiltration of inflammatory cells and myofibroblasts. The pirfenidone-treated group showed less alveolar structural damage, a slight decrease in collagenous lung fibers, a decrease in fibroblasts, and a reduction in the degree of pulmonary fibrosis. The P5-treated group showed less alveolar structural damage, a slight decrease in collagenous lung fibers, a decrease in fibroblasts, and a similar reduction in the degree of pulmonary fibrosis. The E5-treated group showed clearer lung tissue structure, a significant decrease in collagenous lung fibers, and a significant decrease in fibroblasts, with the overall lung condition approaching that of the blank group. The above data show that the pirfenidone analogue P5 developed by the present invention has a certain effect in alleviating pulmonary fibrosis. Although the chemical structure of P5 has been reported, its anti-pulmonary fibrosis research has not yet been carried out. The endoperoxide E5 developed based on P5 has a more excellent anti-pulmonary fibrosis effect, and its anti-pulmonary fibrosis effect is more significant than that of the listed drug pirfenidone. The degree of fibrosis in lung tissue after treatment is greatly alleviated.
[0140] 4.2.5 Safety Assessment
[0141] Comparison with a standard was used to analyze serum parameters and assess drug safety. Compared to the model group, serum AST, ALT, AKP, BUN, and SCR levels in the pirfenidone, P5, and E5 treatment groups were significantly decreased, reaching levels comparable to those in the blank group, demonstrating the safety of E5 (Figure 6).
[0142] Changes in mouse body weight during the experiment can be used to assess the effects of drug use on mice. Compared to the blank control group, none of the three treatment groups (pirfenidone, P5, and E5) showed significant weight loss, further demonstrating the excellent safety of the new drug E5.
[0143] Example 5: Anti-lung cancer experiment
[0144] 5.1 Testing the cytotoxicity of endoperoxides against A549 human lung cancer cells: A549 cells were cultured in 96-well plates overnight to allow complete cell adhesion. Gradient concentrations of endoperoxide E were then added to the cells and incubated for 24 hours. Finally, the cytotoxicity of the compounds was tested using the MTT assay. As shown in Figure 7a, the representative endoperoxide E5 exhibited excellent anticancer properties, with an IC of 0. 50 The series of compounds all showed good anticancer properties, and the anticancer ability tests of some compounds are shown in Table 2.
[0145] 5.2 Endoperoxides inhibit HIF-1α expression and alleviate tumor hypoxia: A549 cells were cultured in 96-well plates overnight under hypoxic conditions. Endoperoxides were then added to the cells and incubated for another 24 hours. HIF-1α expression was analyzed by Western blotting. The results showed that E5 could effectively inhibit HIF-1α (Figure 7b). Experiments using NaN3 as a singlet oxygen quencher demonstrated that triplet oxygen released by E5 is the main component that inhibits HIF-1α.
[0146] 5.3 Singlet Oxygen Release by Endoperoxides in A549 Human Lung Cancer Cells: A549 cells were cultured overnight in a confocal microplate. Endoperoxide E and the raw material control P (40 μM) were added and incubated for 5 hours, then washed with PBS. The cells were then stained with a 10 μM DCFH-DA solution for 45 minutes and then incubated with a 10 μg / mL Hoechst solution at room temperature for 20 minutes before being photographed under a fluorescence microscope. As shown in Figure 7c, cells treated with compound E5 exhibited significant singlet oxygen release, while no significant singlet oxygen release was observed with the control compound.
[0147] 5.4 Endoperoxide-Promoted Apoptosis in A549 Human Lung Cancer Cells: Cells were cultured overnight in a confocal microplate. Endoperoxide E and the raw material control P (160 μM each) were then added to the cells and incubated for 9 hours. The drugs were then removed and the cells washed with PBS. Annexin V-FITC / PI staining solution was then added, and the cells were incubated in the dark at room temperature for 20 minutes before being photographed under a fluorescence microscope. As shown in Figure 7d, compound E5 significantly promoted apoptosis in A549 cells.
[0148] 5.5 Establishment of the A549 nude mouse model and in vivo anticancer effects of endoperoxides
[0149] Balb / c nude mice were selected and A549 (6×105 ) cell suspension was inoculated subcutaneously on the right dorsal side of nude mice near the axilla to create a model. The tumor-bearing mice were randomly divided into three groups (model control group, N-substituted phenyl-2-pyridone treatment group, and N-substituted phenyl-2-pyridone endoperoxide treatment group), with five mice in each group. When the tumor grew to 100 cm 3 Treatment began at 1:00 p.m. with the drug diluted in 0.5% sodium carboxymethylcellulose (CMC-Na) solution. The model control group received the same volume of sodium carboxymethylcellulose solution by gavage. Dosing was performed every two days, and tumor volume and mouse body weight were monitored. After treatment, the mice were sacrificed, and the tumors were removed and weighed. As shown in Figure 8, tumor volume decreased in the N-substituted phenyl-2-pyridone P5-treated group (approximately 10% reduction compared to the model group), while tumor volume decreased significantly in the N-substituted phenyl-2-pyridone endoperoxide E5-treated group (approximately 80% reduction compared to the model group) (Figures 8a-8b). Staining of tumor sections confirmed E5's potent anticancer and hypoxia-reducing properties (Figures 8c-8d). Furthermore, mouse body weight, serum biochemistry, and HE staining of other organs in both treatment groups showed no significant changes compared to the model control group (Figures 9a-9b). These results demonstrate that the N-substituted phenyl-2-pyridone endoperoxide developed by the present invention possesses excellent in vivo therapeutic potential for lung cancer and possesses an excellent safety profile. The anti-lung cancer experimental results of other compounds are shown in Table 2.
[0150] Table 2 Anti-lung cancer experimental results of a series of compounds Note: A represents the IC of the compound 50 <100 μM; B represents the IC of the compound 50 100-150 μM; C represents the IC of the compound 50 150-200 μM; D represents the IC of the compound 50 >200μM; Whether it has in vivo anti-lung cancer ability is evaluated by inhibiting tumor growth in tumor-bearing mice, and "yes" indicates that it can inhibit the growth of nude mouse A549 tumor.
[0151] Example 6
[0152] The synthesis of the series of compounds is described in patent document CN114716365A:
[0153] Example 7
[0154] Anti-cancer experiments:
[0155] To establish a mouse lung cancer model, 6-8 week old Balb / c male nude mice were subcutaneously inoculated with A549 cell suspension (1×10 7A549 tumor-bearing mice were randomly divided into two groups: a 0.5% sodium carboxymethylcellulose group (control group) and a drug-treated group, each receiving a 300 mg / kg dose. Fourteen days after drug administration, the tumor-bearing mice were sacrificed by exsanguination, and blood, tumors, and other organs were collected for analysis of the compound's anticancer activity.
[0156] Analysis of the anti-lung cancer results of the representative compound P10
[0157] The results showed that the volume of the mice in both groups increased, but the growth was slower in the P10-treated group. As shown in Figures 10a-10c, tumor growth in the treated mice was significantly inhibited, demonstrating that the drug P10 can slow tumor growth and has anti-cancer efficacy.
[0158] Safety evaluation of representative compound P10
[0159] HE staining was performed on the heart, liver, lung, spleen and kidney tissues of the blank group and P10 treatment group mice respectively to evaluate the effects of the drug on other organs and prove the safety of the drug (Figure 11a). Compared with the blank group, continuous use of P10 did not cause obvious damage to other organs of the mice, proving that P10 has good safety. There was no significant difference in the levels of AST, ALT, BUN and SCR in the plasma of the treated mice and the blank group, proving that the drug P10 has good safety (Figure 11b). Compared with the blank group, there was no significant weight loss in the P10 treatment group, further demonstrating the excellent safety of the new drug P10 (Figure 11c).
[0160] Example 8
[0161] The anti-lung cancer test data of other compounds are given in the form of the following table, wherein the test process and method refer to Example 7, using breast cancer cell MCF7, liver cancer cell HepG2, prostate cancer cell LNCap and pancreatic cancer cell PANC-1 to construct corresponding cancer models, respectively, to evaluate the anti-cancer universality of the series of compounds.
[0162] Table 3 Anticancer data of a series of compounds In anti-cancer experiments, "yes" means that the drug can inhibit tumor growth, and "no" means that it cannot inhibit tumor growth.
[0163] Example 9
[0164] Liver fibrosis treatment experiment
[0165] Carbon tetrachloride (CCl4) was used to induce liver fibrosis in mice, and the therapeutic effect of compound P10 on liver fibrosis was evaluated as follows: Male mice were randomly divided into three groups, each with 10 mice: a blank group, a CCl4 model group, and a P10-treated group. The CCl4 model group and the P10-treated group were treated with CCl4 (3 mL / kg, twice weekly for 4 weeks) for 4 weeks to establish a liver fibrosis model. During treatment, the P10-treated group was administered with a 5% sodium carboxymethylcellulose (CMC-Na) solution of P10 (400 mg / kg), while the blank group and the CCl4 model group were gavaged with the same dose of CMC-Na solution. The weight and survival of the mice were measured during oral gavage. The mice were killed 14 days after medication. The eyeballs of the mice were removed to collect blood and the serum was separated. The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) indicators were measured to determine the degree of liver damage. The LN (laminin) and total bilirubin (TBIL) indicators were measured to evaluate the degree of liver fibrosis. The livers of the mice were removed and the hydroxyproline (HYP) content was measured.
[0166] Analysis of treatment results for liver fibrosis
[0167] As shown in Table 4, the serum ALT and AST levels of mice in the P10-treated group were significantly lower than those in the CCl4 model group. P10 significantly inhibited the CCl4-induced increase in ALT and AST in mice, alleviating liver damage. LN (laminin) and total bilirubin (TBIL) were significantly reduced in the treated group. Compared with the blank control group, the hydroxyproline content in the liver of mice in the CCl4 model group was significantly increased. After P10 administration, the hydroxyproline content was significantly reduced, indicating that P10 can reduce the content of hydroxyproline in liver tissue, inhibit the formation of collagen fibers in the mouse liver, and thus inhibit liver fibrosis.
[0168] Table 4 Data of representative compound P10 on alleviating liver fibrosis
[0169] Example 10
[0170] The test data of other compounds for treating liver fibrosis are given in the form of the following table, wherein the test process and method refer to Example 8.
[0171] Table 5 Data of other compounds for the treatment of liver fibrosis In the liver fibrosis experiment, "yes" means that the drug can inhibit liver fibrosis, and "no" means that it cannot inhibit liver fibrosis.
[0172] Example 11
[0173] Experimental study on the treatment of renal fibrosis and analysis of the results
[0174] Rats were randomly divided into three groups, each consisting of 10 rats: a blank group, a model group, and a P10-treated group. The model and P10-treated groups were established using a unilateral ureteral ligation method: rats were anesthetized, the abdomen disinfected, the hair shaved, and the skin exposed. In the lateral decubitus position, an incision was made in the left renal region to enter the abdominal cavity. The lower edge of the kidney was exposed, and the ureter was located. The ureter was ligated at the proximal and distal ends of the kidney, and the wound was sutured. Three weeks later, a renal fibrosis model was established. During treatment, the P10-treated group was administered with a 5% sodium carboxymethylcellulose (CMC-Na) solution of P10 (400 mg / kg), while the blank and model groups were gavaged with the same dose of CMC-Na solution. During gavage, the mice's body weight and survival were measured. After 14 days of treatment, the mice were sacrificed, their eyes enucleated, and blood was collected. Serum was separated for determination of urea nitrogen (BUN) and creatinine (Scr) levels, and the degree of renal fibrosis was analyzed. As shown in Table 4 , the serum BUN and Scr levels of mice in the P10 treatment group were significantly lower than those in the model group, demonstrating that P10 can improve glomerular and tubular damage and reduce renal fibrosis and inflammatory cell infiltration.
[0175] Table 6 Data of representative compound P10 on alleviating renal fibrosis
[0176] Example 12
[0177] The test data of other compounds for alleviating renal fibrosis are given in the form of the following table, wherein the test process and method refer to Example 11.
[0178] Table 7 Data of other compounds alleviating renal fibrosis In the renal fibrosis experiment, "yes" means that the drug can reduce renal fibrosis and the infiltration of inflammatory cells, and "no" means that it cannot reduce renal fibrosis and the infiltration of inflammatory cells.
[0179] Example 13
[0180] Experimental study on the treatment of myocardial fibrosis and analysis of the results
[0181] An in vitro myocardial fibrosis model was established using TGF-β1-induced mouse cardiac fibroblasts. The experiment was divided into a control group, a model group, and a P10-treated group. Cells in the model group were incubated with TGF-β1 (10 ng / ml), while cells in the P10-treated group were incubated with TGF-β1 (10 ng / ml) and compound P10. RNA was extracted and used for reverse transcription and amplification to measure α-SMA, collagen I, and collagen III mRNA expression levels.
[0182] As shown in Table 8, α-SMA, collagen I, and collagen III levels were significantly increased in TGF-β1-treated cardiac fibroblasts, confirming the establishment of a myocardial fibrosis model. In the treatment group, these factors were significantly suppressed, approaching normal levels, demonstrating that compound P10 can inhibit the expression of myocardial fibrosis biomarkers and has an anti-myocardial fibrosis effect.
[0183] Table 8 Data of representative compound P10 on alleviating myocardial fibrosis
[0184] Example 14
[0185] The test data of other compounds for treating myocardial fibrosis are given in the following table, wherein the test process and method refer to Example 13.
[0186] Table 9 Data of other compounds for the treatment of myocardial fibrosis In the myocardial fibrosis experiment, "yes" means that the drug can inhibit the expression of myocardial fibrosis biomarkers and has an anti-myocardial fibrosis effect, and "no" means that it has an anti-myocardial fibrosis effect.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt thereof: in, R 1 , R 3 Each independently selected from hydrogen, deuterated methyl, C1-C10 alkyl, carboxyl, C1-C5 fluoroalkyl, nitro, C1-C10 ester; R 4 -R 8 Each independently selected from hydrogen, C1-C5 deuterated alkyl, C1-C5 fluoroalkyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C10 alkylamino, nitro, cyano, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 thioether; R is independently a C1-C5 alkyl group.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: R 1 , R 3 Each independently selected from hydrogen, deuterated methyl, C1-C5 alkyl, trifluoromethyl, and carboxyl; R 4 -R 8 Each independently selected from hydrogen, C1-C5 deuterated alkyl, C1-C5 fluoroalkyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C10 alkylamino, nitro, cyano, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 thioether; R is independently a C1-C5 alkyl group.
3. [Corrected 30.07.2024 in accordance with Rule 91] A compound according to claim 2 or a pharmaceutically acceptable salt thereof, characterized in that R 1 , R 3 Each is independently selected from hydrogen, deuterated methyl, trifluoromethyl, methyl, and carboxyl.
4. [Corrected 30.07.2024 in accordance with Rule 91] A compound according to claim 3 or a pharmaceutically acceptable salt thereof, characterized in that R 4 -R 8 Each is independently selected from hydrogen, deuterated methyl, trifluoromethyl, halogen, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, amino, -COOR, -CONR, C1-C5 alkylamino, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 thioether; R is independently a C1-C5 alkyl group.
5. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, characterized in that: R 1 , R 3 Each is independently selected from hydrogen and methyl.
6. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, characterized in that: R 4 -R 8 Each is independently selected from hydrogen, deuterated methyl, methyl, ethyl, tert-butyl, trifluoromethyl, F, Cl, carboxyl, sulfonic acid, aminosulfonic acid, hydroxyl, -COOCH3, -COOtBu, -CONHCH3, methoxy, ethoxy, nitro, and cyano.
7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, characterized in that: The compound is selected from the following structures:
8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof, characterized in that: The compound is selected from the following structures:
9. The method for preparing the compound according to any one of claims 1 to 8, characterized in that: The following steps are involved: (1) Compound 1 and Compound 2 react in the presence of potassium carbonate and cuprous iodide to obtain Compound P; (2) Compound P reacts in the presence of a photosensitizer, an oxygen environment, and irradiation conditions to obtain compound E; Among them, R 1 , R 3 , R 4 -R 8 The definition of is the same as that in formula I.
10. The preparation method according to claim 9, characterized in that: In the step (2), the reaction solvent is selected from one or more of chloroform, dichloromethane, ether, methanol, ethanol, toluene, benzene, DMF, ethyl acetate, water, and deuterated reagents; The deuterated reagent is selected from one or more of deuterated chloroform, deuterated methanol, deuterated benzene, and deuterated water; The reaction temperature is -20°C to room temperature; The wavelength of the red light source is 425-750nm, and the oxygen environment is oxygen, oxygen-containing gas or direct open reaction; The photosensitizer is selected from methylene blue, fluoroborax, hematoporphyrin, dihydrochlorin e6, pyropheophorbide-a, pyropheophorbide a hexyl ether, phenothiazine derivatives, phenoxazine derivatives, porphyrin photosensitizers or phthalocyanine photosensitizers.
11. The method according to claim 10, characterized in that The reaction was carried out in an ice-water bath, an ice bath, a room temperature water bath or at 0°C; The photosensitizer is methylene blue, and the wavelength of the red light source is 620-625nm.
12. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof.
13. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a drug that is converted into N-substituted phenyl-2-pyridone in vivo and releases singlet oxygen and triplet oxygen: in, R 1 , R 3 , R 4 -R 8 The definition of is the same as that in formula I.
14. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of the following medicaments: Drugs that inhibit the expression of transforming growth factor-β (TGF-β), monocyte chemoattractant protein-1 (MCP-1), serum inflammatory factor interleukin-1β (IL-1β), and upregulate heme oxygenase-1 (HO-1); or Drugs for treating or improving diseases or inflammation involving one or more factors including TGF-β, MCP-1, IL-1β, HO-1, TNF-α, IL-6, IFN-γ, bFGF, PDGF, NLRP3, CAT, and SOD.
15. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a drug for improving or treating fibrosis.
16. The use according to claim 15, characterized in that The fibrosis is pulmonary fibrosis, renal interstitial fibrosis, liver fibrosis, renal fibrosis, and myocardial fibrosis.
17. The use according to claim 16, characterized in that The pulmonary fibrosis is idiopathic pulmonary fibrosis.
18. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating cancer.
19. The use according to claim 18, characterized in that The cancer is non-small cell lung cancer, breast cancer, liver cancer, prostate cancer, and pancreatic cancer.
20. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating idiopathic pulmonary fibrosis combined with lung cancer.
21. The use according to any one of claims 14 to 20, characterized in that: The medicine is in the form of tablets, capsules, granules, powders, oral preparations, injections, microcapsule preparations, suppositories, pills, aerosols, sprays, powder inhalers, syrups, wine preparations, tinctures, lotions, and films. One or more of the above dosage forms are selected for treatment.
22. The use according to any one of claims 14 to 20, characterized in that: The drugs include: At least one of the compounds of formula I; and / or carrier; and / or Pharmaceutical excipients; The carrier is selected from one or more of metal nanocarriers, non-metal nanocarriers, liposomes, lactose, sucrose, gelatin, hard magnesium sulfate, and stearic acid; The pharmaceutical excipients are selected from one or more of diluents, adhesives, disintegrants, lubricants, glidants, flavoring agents, coating agents, gelatin capsule shells, latent solvents, propellants, surfactants, preservatives, and freeze-drying protective agents.
23. The use according to any one of claims 14 to 20, characterized in that: The medicine is prepared into a liposome or micelle form.
24. Use of the compound of formula II in the preparation of drugs for treating liver fibrosis, kidney fibrosis, myocardial fibrosis, lung cancer, breast cancer, liver cancer, prostate cancer, and pancreatic cancer: in, R 9 , R 10 , R 11 , R 12 , R 13 Each is independently a hydrogen atom, a methyl group, an ethyl group, a deuterated methyl group, a trifluoromethyl group, a butyl group, a halogen group, a hydroxyl group, a cyano group, an amino group, a carboxyl group, a methoxy group, an ethoxy group, or a methylthio group.
25. The use according to claim 24, characterized in that The compound of formula II is selected from the following structures:
26. The use according to claim 24, characterized in that The compound of formula II is selected from the following structures:
27. The use according to claim 24, characterized in that The compound of formula II is selected from the following structures:
28. A drug for treating liver fibrosis, kidney fibrosis, myocardial fibrosis, lung cancer, breast cancer, liver cancer, prostate cancer or pancreatic cancer, characterized in that: Contains at least one of the compounds of formula II or pharmaceutically acceptable salts thereof.
29. The use according to any one of claims 24 to 28, characterized in that: The dosage form of the medicine is tablet, capsule, granule, powder, oral preparation, injection, microcapsule preparation or suppository.
30. The use according to any one of claims 24 to 28, characterized in that: The drug is administered orally, by intravenous injection, by respiratory inhalation, by topical administration or by sublingual administration.
31. [Corrected 30.07.2024 in accordance with Rule 91] The use according to any one of claims 24 to 28, characterized in that The drug is prepared into a liposome or micelle form; the liposome or micelle form drug comprises at least one of the compounds of formula II; and / or carrier; and / or Pharmaceutical excipients; The carrier is selected from one or more of metal nanocarriers, non-metal nanocarriers, micelles, liposomes, lactose, sucrose, gelatin, hard magnesium sulfate, and stearic acid; The pharmaceutical excipients are selected from one or more of diluents, adhesives, disintegrants, lubricants, glidants, flavoring agents, coating agents, gelatin capsule shells, latent solvents, propellants, surfactants, preservatives, and freeze-drying protective agents.
32. [Corrected 30.07.2024 in accordance with Rule 91] The use according to any one of the preceding claims, characterized in that The medicine is prepared into a liposome or micelle form.
Citation Information
Patent Citations
Pyridone derivatives for modulating stress-activated protein kinase system
CN101237869A
Compounds and methods for treating inflammatory and fibrotic disorders
CN102099036A
Application of N-substituted phenyl-2-pyridone compounds or pharmaceutically acceptable salts thereof in treatment of pulmonary fibrosis
CN114716365A
N-substituted phenyl-2-pyridone endoperoxide and application thereof
CN116655654A
Application of 1-(substituted phenyl)-5-methyl-2-(1H)-pyridone compound in preparing medicine for anti-other organifibrosis and tissue fibrosis except renal interstitial fibrosis
CN1846699A
